Bayer PE Ratio 2012-2026 | BAYRY
Current and historical p/e ratio for Bayer (BAYRY) from 2012 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Bayer PE ratio as of September 14, 2026 is 9.98.
| Bayer PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-09-14 | 14.27 | 0.00 | |
| 2026-06-30 | 13.70 | $-0.44 | 0.00 |
| 2026-03-31 | 11.45 | $-0.57 | 0.00 |
| 2025-12-31 | 10.79 | $-1.04 | 0.00 |
| 2025-09-30 | 8.27 | $0.44 | 18.98 |
| 2025-06-30 | 7.52 | $-0.45 | 0.00 |
| 2025-03-31 | 5.97 | $-0.91 | 0.00 |
| 2024-12-31 | 4.84 | $-0.70 | 0.00 |
| 2024-09-30 | 8.40 | $-0.75 | 0.00 |
| 2024-06-30 | 6.99 | $-0.84 | 0.00 |
| 2024-03-31 | 7.57 | $-0.85 | 0.00 |
| 2023-12-31 | 9.12 | $-0.81 | 0.00 |
| 2023-09-30 | 11.86 | $-1.08 | 0.00 |
| 2023-06-30 | 13.66 | $0.32 | 42.10 |
| 2023-03-31 | 15.14 | $0.77 | 19.71 |
| 2022-12-31 | 12.22 | $1.11 | 10.99 |
| 2022-09-30 | 10.98 | $1.35 | 8.13 |
| 2022-06-30 | 14.13 | $1.24 | 11.43 |
| 2022-03-31 | 15.72 | $0.60 | 26.23 |
| 2021-12-31 | 12.18 | $0.30 | 40.36 |
| 2021-09-30 | 12.49 | $-0.03 | 0.00 |
| 2021-06-30 | 14.00 | $-0.87 | 0.00 |
| 2021-03-31 | 14.06 | $-2.83 | 0.00 |
| 2020-12-31 | 13.14 | $-3.05 | 0.00 |
| 2020-09-30 | 13.24 | $-2.64 | 0.00 |
| 2020-06-30 | 16.49 | $-1.57 | 0.00 |
| 2020-03-31 | 12.24 | $1.23 | 9.98 |
| 2019-12-31 | 17.16 | $1.17 | 14.69 |
| 2019-09-30 | 14.97 | $-0.53 | 0.00 |
| 2019-06-30 | 14.76 | $0.06 | 248.96 |
| 2019-03-31 | 13.01 | $0.20 | 63.73 |
| 2018-12-31 | 14.19 | $0.53 | 26.70 |
| 2018-09-30 | 17.88 | $2.00 | 8.95 |
| 2018-06-30 | 22.28 | $2.45 | 9.09 |
| 2018-03-31 | 21.88 | $2.58 | 8.49 |
| 2017-12-31 | 24.08 | $2.38 | 10.13 |
| 2017-09-30 | 26.50 | $2.31 | 11.48 |
| 2017-06-30 | 25.15 | $1.40 | 17.95 |
| 2017-03-31 | 21.81 | $1.49 | 14.66 |
| 2016-12-31 | 19.73 | $1.51 | 13.11 |
| 2016-09-30 | 19.01 | $1.59 | 11.97 |
| 2016-06-30 | 19.04 | $1.53 | 12.48 |
| 2016-03-31 | 21.68 | $1.44 | 15.07 |
| 2015-12-31 | 23.08 | $1.38 | 16.73 |
| 2015-09-30 | 23.67 | $1.23 | 19.29 |
| 2015-06-30 | 26.06 | $1.22 | 21.32 |
| 2015-03-31 | 25.39 | $1.23 | 20.60 |
| 2014-12-31 | 23.12 | $1.38 | 16.80 |
| 2014-09-30 | 23.67 | $1.51 | 15.71 |
| 2014-06-30 | 23.87 | $1.47 | 16.23 |
| 2014-03-31 | 22.36 | $1.41 | 15.87 |
| 2013-12-31 | 23.47 | $1.28 | 18.31 |
| 2013-09-30 | 19.50 | $1.23 | 15.82 |
| 2013-06-30 | 17.63 | $1.14 | 15.49 |
| 2013-03-31 | 16.71 | $1.00 | 16.75 |
| 2012-12-31 | 15.48 | $0.95 | 16.26 |
| 2012-09-30 | 13.86 | $0.97 | 14.26 |
| 2012-06-30 | 11.53 | $1.05 | 11.02 |
| 2012-03-31 | 10.98 | $1.18 | 9.32 |
| 2011-12-31 | 9.97 | $1.05 | 9.52 |
| 2011-09-30 | 8.56 | $0.80 | 10.67 |
| 2011-06-30 | 12.59 | $0.64 | 19.74 |
| 2011-03-31 | 11.84 | $0.51 | 23.11 |
| 2010-12-31 | 11.18 | $0.51 | 22.14 |
| 2010-09-30 | 10.62 | $0.65 | 16.27 |
| 2010-06-30 | 8.50 | $0.66 | 12.98 |
| 2010-03-31 | 10.01 | $0.68 | 14.67 |
| 2009-12-31 | 11.81 | $0.59 | 20.19 |
| 2009-09-30 | 10.30 | $0.56 | 18.32 |
| 2009-06-30 | 7.93 | $0.59 | 13.45 |
| 2009-03-31 | 6.82 | $0.65 | 10.54 |
| 2008-12-31 | 8.48 | $0.83 | 10.25 |
| 2008-09-30 | 10.46 | $0.79 | 13.33 |
| 2008-06-30 | 12.03 | $1.15 | 10.49 |
| 2008-03-31 | 11.20 | $1.14 | 9.80 |
| 2007-12-31 | 12.66 | $1.91 | 6.63 |
| 2007-09-30 | 11.04 | $1.91 | 5.78 |
| 2007-06-30 | 10.47 | $1.54 | 6.79 |
| 2007-03-31 | 8.72 | $1.45 | 6.00 |
| 2006-12-31 | 7.27 | $0.57 | 12.71 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $56.081B | $51.552B |
| Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1071.528B | 36.15 |
| Johnson & Johnson (JNJ) | United States | $641.804B | 24.52 |
| AbbVie (ABBV) | United States | $462.493B | 24.08 |
| Merck (MRK) | United States | $357.370B | 45.12 |
| Roche Holding AG (RHHBY) | Switzerland | $349.105B | 0.00 |
| Novartis AG (NVS) | Switzerland | $265.214B | 16.01 |
| Novo Nordisk (NVO) | Denmark | $194.004B | 10.81 |
| Pfizer (PFE) | United States | $157.995B | 9.09 |
| Sanofi (SNY) | France | $105.050B | 8.84 |
| Innoviva (INVA) | United States | $1.510B | 5.16 |